查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1991413

全球关节内粘稠补充疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Viscosupplementation Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 114 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年，关节内粘稠补充疗法市场规模将达到 157.2 亿美元，高于 2025 年的 66.2 亿美元，预计从 2026 年到 2034 年的复合年增长率将达到 10.09%。

随着骨关节炎盛行率的不断上升，尤其是在老年人族群中，全球关节内粘稠补充疗法市场正稳步成长。关节内粘稠补充疗法是将透明质酸注射到关节（尤其是膝关节）中，以改善关节润滑并减轻疼痛。当止痛药和物理治疗等传统治疗方法效果不佳时，这种治疗方法被广泛使用。人们对微创治疗的日益关注以及对有效关节疼痛管理的需求，都推动了该市场的扩张。

推动这一市场成长的关键因素包括全球骨关节炎和关节疾病负担的日益加重。人口老化和肥胖率上升也推动了对关节治疗方案的需求。患者和医疗专业人员越来越多地选择关节内粘稠补充疗法作为非手术治疗关节疼痛的方法。透明质酸配方的改进和注射效果持续时间的延长也有助于提高治疗效果和患者满意度。

未来几年，关节内粘稠补充疗法市场有望受益于整形外科治疗的持续进步。专注于改善注射剂配方和延长治疗疗程的研究有望提升临床疗效。医疗保健服务的普及和对保守关节疗法认知度的提高将促进该疗法的应用。随着患者寻求创伤较小的关节疼痛管理方法并维持活动能力，关节内粘稠补充疗法预计仍将是重要的治疗选择。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章 全球关节内粘稠补充疗法市场：依产品划分

  • 市场分析、洞察与预测
  • 单次注射
  • 三次注射
  • 五针

第五章：全球关节内粘稠补充疗法市场：依最终用途划分

  • 市场分析、洞察与预测
  • 医院
  • 整形外科诊所/门诊手术中心

第六章 全球关节内粘稠补充疗法市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第七章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第八章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • DePuy Synthes
    • Fidia Farmaceutici SpA
    • Sanofi
    • Smith & Nephew Plc
    • Anika Therapeutics Inc
    • Seikagaku Corporation
    • Zimmer Biomet Holdings Inc
    • Ferring Pharmaceuticals BV
    • Lifecore Biomedical LLC
    • LG Life Sciences Ltd
    • F. Hoffmann-La Roche Ltd
简介目录
Product Code: VMR11213813

The Viscosupplementation Market size is expected to reach USD 15.72 Billion in 2034 from USD 6.62 Billion (2025) growing at a CAGR of 10.09% during 2026-2034.

The global viscosupplementation market has grown steadily as osteoarthritis becomes more prevalent, particularly among aging populations. Viscosupplementation involves injecting hyaluronic acid into joints, especially the knee, to improve lubrication and reduce pain. This treatment option is widely used when conventional therapies such as pain medication or physical therapy provide limited relief. Increasing awareness about minimally invasive treatments and the need for effective joint pain management has contributed to the expansion of this market.

The market is driven by several important factors, including the rising global burden of osteoarthritis and joint disorders. Aging demographics and increasing rates of obesity have led to greater demand for joint treatment solutions. Patients and healthcare providers are increasingly choosing viscosupplementation as a non-surgical alternative for managing joint pain. Improvements in hyaluronic acid formulations and longer-lasting injections have also enhanced treatment effectiveness and patient satisfaction.

In the coming years, the viscosupplementation market is expected to benefit from continued advancements in orthopedic therapies. Research efforts focused on improving injection formulations and extending treatment duration may enhance clinical outcomes. Expanding healthcare access and increasing awareness about joint preservation therapies will likely drive adoption. As patients seek less invasive methods to manage joint pain and maintain mobility, viscosupplementation is expected to remain an important therapeutic option.

MARKET SEGMENTATION

By Product

  • Single Injection
  • Three Injection
  • Five Injection

By End Use

  • Hospitals
  • Orthopedic Clinics/ASCs

COMPANIES PROFILED

  • DePuy Synthes, Fidia Farmaceutici SpA, Sanofi, Smith Nephew plc, Anika Therapeutics Inc, Seikagaku Corporation, Zimmer Biomet Holdings Inc, Ferring Pharmaceuticals BV, Lifecore Biomedical LLC, LG Life Sciences Ltd, F HoffmannLa Roche Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL VISCOSUPPLEMENTATION MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Single Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Three Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Five Injection Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VISCOSUPPLEMENTATION MARKET: BY END USE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End Use
  • 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Orthopedic Clinics/ASCs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VISCOSUPPLEMENTATION MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Product
    • 6.2.2 By End Use
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Product
    • 6.3.2 By End Use
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Product
    • 6.4.2 By End Use
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Product
    • 6.5.2 By End Use
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Product
    • 6.6.2 By End Use
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL VISCOSUPPLEMENTATION INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 DePuy Synthes
    • 8.2.2 Fidia Farmaceutici S.p.A
    • 8.2.3 Sanofi
    • 8.2.4 Smith & Nephew Plc
    • 8.2.5 Anika Therapeutics Inc
    • 8.2.6 Seikagaku Corporation
    • 8.2.7 Zimmer Biomet Holdings Inc
    • 8.2.8 Ferring Pharmaceuticals B.V
    • 8.2.9 Lifecore Biomedical LLC
    • 8.2.10 LG Life Sciences Ltd
    • 8.2.11 F. Hoffmann-La Roche Ltd